| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/14/2013 | CA2461916C Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis |
| 05/14/2013 | CA2455915C Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 05/14/2013 | CA2441562C Short bioactive peptides and methods for their use |
| 05/14/2013 | CA2434303C Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 05/14/2013 | CA2419270C Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof |
| 05/14/2013 | CA2388298C The use of csf-1 inhibitors |
| 05/14/2013 | CA2242342C Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 05/10/2013 | WO2013067537A1 Nanoparticle-based drug delivery |
| 05/10/2013 | WO2013067449A1 Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| 05/10/2013 | WO2013067423A1 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/10/2013 | WO2013067396A2 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/10/2013 | WO2013067308A2 Compositions and methods for inducing disruption of blood vasculature and for reducing angiogenesis |
| 05/10/2013 | WO2013067306A1 Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
| 05/10/2013 | WO2013067277A1 Alkylated piperazine compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067274A1 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067264A1 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067260A1 Bicyclic piperazine compounds |
| 05/10/2013 | WO2013067198A1 Gene signature for the prediction of nf-kappab activity |
| 05/10/2013 | WO2013067165A1 Combination therapy of hsp90 inhibitors with platinum-containing agents |
| 05/10/2013 | WO2013067162A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | WO2013067141A1 N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies |
| 05/10/2013 | WO2013067098A1 Anti-kdr antibodies and methods of use |
| 05/10/2013 | WO2013067055A1 Methods of blocking cancer stem cell growth |
| 05/10/2013 | WO2013067043A1 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/10/2013 | WO2013066903A1 Combinational liposome compositions for cancer therapy |
| 05/10/2013 | WO2013066864A1 Combination anti-cancer therapy |
| 05/10/2013 | WO2013066684A1 Aminopyrimidine kinase inhibitors |
| 05/10/2013 | WO2013066483A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/10/2013 | WO2013066368A1 Use of mirna 126 to produce hematopoietic stem cells |
| 05/10/2013 | WO2013066134A2 Novel cinnamyl-rhodanine derivatives and pharmaceutical composition comprising same as active ingredients |
| 05/10/2013 | WO2013066047A1 Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker |
| 05/10/2013 | WO2013065825A1 Cationic lipid |
| 05/10/2013 | WO2013065019A1 Diagnostic and treatment of an androgen-independent prostate cancer |
| 05/10/2013 | WO2013064919A1 Quinazoline derivatives with hsp90 inhibitory activity |
| 05/10/2013 | WO2013064692A1 Triple combination for the treatment of cancer |
| 05/10/2013 | WO2013064672A2 Oxazaphosphorines dosed one time for treating diseases |
| 05/10/2013 | WO2013064594A1 Gold compounds having alkynyl ligands and therapeutic use thereof |
| 05/10/2013 | WO2013064465A1 New aryl-quinoline derivatives |
| 05/10/2013 | WO2013064445A1 Imidazopyridazine compounds |
| 05/10/2013 | WO2013064083A1 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof |
| 05/10/2013 | WO2013064068A1 Thienopyrimidine and furopyrimidine derivatives, preparation method thereof and medical use thereof |
| 05/10/2013 | WO2013064029A1 Benzoylurea derivative with anticancer activity and preparation method and use thereof |
| 05/10/2013 | WO2013063874A1 Monoclonal antibody against human non-small-cell lung carcinoma and use thereof |
| 05/10/2013 | WO2013063702A1 Stable heterodimeric antibody design with mutations in the fc domain |
| 05/10/2013 | WO2013063679A1 Use of neul sialidase inhibitors in the treatment of cancer |
| 05/10/2013 | WO2013040439A3 CBP and p300-MEDIATED TRANSCRIPTION MODULATORS AND RELATED METHODS |
| 05/10/2013 | WO2013040436A3 Esx-mediated transcription modulators and related methods |
| 05/10/2013 | WO2013040286A3 Pharmaceutical compositions |
| 05/10/2013 | WO2013013238A3 Compounds and related compositions and methods of use |
| 05/10/2013 | WO2013012628A3 Immune-stimulating photoactive hybrid nanoparticles |
| 05/10/2013 | WO2013010018A3 Compositions and methods for inhibiting proteases |
| 05/10/2013 | WO2013005170A4 Inhibitors of aquaglyceroporins, methods and uses thereof |
| 05/10/2013 | WO2012161545A9 Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna |
| 05/10/2013 | WO2012158933A3 Macrocycllc therapeutic agents and methods of treatment |
| 05/10/2013 | CA2858246A1 Use of neu1 sialidase inhibitors in the treatment of cancer |
| 05/10/2013 | CA2854471A1 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/10/2013 | CA2854461A1 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/10/2013 | CA2854233A1 Stable heterodimeric antibody design with mutations in the fc domain |
| 05/10/2013 | CA2854163A1 Compositions and methods for inducing disruption of blood vasculature and for reducing angiogenesis |
| 05/10/2013 | CA2854159A1 N- (3-{[(3-{[2-chloro-5-(methoxy)phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3- kinase inhibitor for the treatment of lymphoproliferative malignancies |
| 05/10/2013 | CA2854153A1 Anti-kdr antibodies and methods of use |
| 05/10/2013 | CA2854066A1 Cationic lipid |
| 05/10/2013 | CA2854059A1 Diagnostic and treatment of an androgen-independent prostate cancer |
| 05/10/2013 | CA2853975A1 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853970A1 Alkylated piperazine compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853967A1 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853949A1 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/10/2013 | CA2853806A1 Combination therapy of hsp90 inhibitors with platinum-containing agents |
| 05/10/2013 | CA2853799A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | CA2853491A1 Methods for treatment of diseases and disorders related to transducin .beta.-like protein 1 (tbl1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia |
| 05/10/2013 | CA2853454A1 Aminopyrimidine kinase inhibitors |
| 05/10/2013 | CA2852964A1 Bicyclic piperazine compounds |
| 05/10/2013 | CA2850955A1 Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| 05/10/2013 | CA2849945A1 New aryl-quinoline derivatives |
| 05/10/2013 | CA2849194A1 Imidazopyridazine compounds |
| 05/10/2013 | CA2846454A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/10/2013 | CA2846074A1 Compositions and methods for treatment of metastatic cancer |
| 05/09/2013 | US20130116309 Oligomeric compounds for the modulation of hif-1a expression |
| 05/09/2013 | US20130116268 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 05/09/2013 | US20130116263 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/09/2013 | US20130116243 Inhibitors of akt activity |
| 05/09/2013 | US20130116237 [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| 05/09/2013 | US20130116208 Administration of a nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/09/2013 | US20130116203 Isothiocynates and glucosinolate compounds and anti-tumor compositions containing same |
| 05/09/2013 | US20130116196 Muscle fatigue substance cytokines and methods of inhibiting tumor growth therewith |
| 05/09/2013 | US20130115696 siRNA that Inhibits WT1 Gene Expression and Uses Thereof |
| 05/09/2013 | US20130115224 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/09/2013 | US20130115221 HIFa prolyl hydroxylation assay |
| 05/09/2013 | US20130115216 Survivin-derived peptides and uses thereof |
| 05/09/2013 | US20130115191 T cell receptor fusions and conjugates and methods of use thereof |
| 05/08/2013 | EP2589963A1 Diagnostic and treatment of an androgen-independent prostate cancer |
| 05/08/2013 | EP2589658A1 Partial region polypeptide of reic/dkk-3 protein |
| 05/08/2013 | EP2589610A1 Human c-fms antigen binding proteins |
| 05/08/2013 | EP2589605A1 Telomerase activity inhibiting peptide and manufacturing method and application thereof |
| 05/08/2013 | EP2589391A2 Method for treating and diagnosing cancer by using cell-derived microvesicles |
| 05/08/2013 | EP2589388A1 Use of a Teichoic acid for the treatment of malignant ascites |
| 05/08/2013 | EP2589387A1 Use of a teichoic acid for the treatment of malignant liquor cerebrospinalis in the brain |
| 05/08/2013 | EP2589385A1 Triple combination for the treatment of cancer |
| 05/08/2013 | EP2589384A1 New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders |
| 05/08/2013 | EP2589383A1 FKBP subtype-specific rapamycin analogue for use in treatment of diseases |